L-Carnitine Protective Effect in Nephrotoxicity
ConditionNephrotoxicity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTanta University
About this trial
The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is:
Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female patients.
Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy.
Age between 18 and 75 years.
No serious cardiopulmonary comorbidity which could impair involvement in the study.
Disqualifiers
Pregnancy or lactation.
Metastasis to the central nervous system.
Psychiatric disorders.
Prior treatment with platinum derivatives.
Trial design
Design model
Parallel
Treatments tested in this trial
L-Carnitine Tartrate
DrugL-carnitine 350 mg three times daily by oral.
Placebo
Drugplacebo tablet three times daily by oral.
Treatment groups
46 Participants
are divided into 2 treatment groupsGroup A: L-carnitine groupActive comparator 1 intervention
Group B: Placebo groupPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
change in serum creatinine and creatinine clearance
serum creatinine average ranges are 0.7 to 1.2 (mg/dL) for males and 0.5 to 1.0 for females.
Time frame
Baseline (before chemotherapy cycles)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov